September 15, 2006

Takeda Pharmaceuticals North America
Takeda Pharmaceutical Company Limited

ACTOS^® (pioglitazone HCl) Demonstrates Significant Improvements in Cardiovascular Outcomes for High-Risk Patients with Type 2 Diabetes

Results presented at the 42nd European Association for the Study of Diabetes Annual Meeting

Copenhagen, Denmark, September 14, 2006 --- Several abstracts presented today at the 42nd Annual Meeting of the European Association for the Study of Diabetes (EASD) indicated that ACTOS® (pioglitazone HCl), an oral antidiabetic medication, demonstrated significant cardiovascular benefits such as reducing the risk of heart attack and/or stroke and acute coronary syndrome in patients with type 2 diabetes. Cardiovascular disease (CVD) is the leading cause of premature death in patients with diabetes. An estimated 171 million people worldwide have diabetes, and CVD is responsible for 50% to 80% of deaths in people with diabetes.

"We are continuing to see the benefits of ACTOS beyond glycemic control," said Erland Erdmann, M.D., chairman of the PROactive Executive Committee and director of the Clinic III for Internal Medicine, University of Cologne, Germany. "We know that patients with diabetes are two to four times more likely to develop heart disease or have a stroke than people without diabetes. The data presented at EASD showed that ACTOS can have a positive effect on several measures of cardiovascular disease outcomes in high-risk patients with type 2 diabetes."

Reduced Occurrence of Major Adverse Cardiovascular Events (MACE)

Results from one of the studies showed that ACTOS significantly reduced the occur-rence of major adverse cardiovascular events (MACE), such as heart attacks, nonfatal stroke, acute coronary syndrome and cardiovascular death in high-risk patients with type 2 diabetes. Compared to placebo, patients treated with ACTOS demonstrated statistically significant risk reductions of heart attacks (23 percent, P=0.046), the combined risk of cardiovascular death, nonfatal heart attack or nonfatal stroke (18 percent, P=0.020) and the combined risk of all-cause mortality, nonfatal heart attack, nonfatal stroke or acute coronary syndrome (17 percent, P=0.010). These results were part of the landmark PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Events) study.

Decreased Incidence of Heart Attacks

Compared with the general population, individuals with type 2 diabetes have an increased incidence of myocardial infarction (MI), commonly known as a heart attack. In patients who had experienced a previous heart attack, ACTOS, on top of standard-of-care treatment, reduced the recurrence of fatal or non fatal (excluding silent MI) heart attacks by 28 percent (P=0.045).

Prevented Recurrent Strokes

Patients with diabetes have a markedly higher risk of stroke than those without. In fact, strokes occur twice as often in people with diabetes. Of the estimated 750,000 people in the U.S. who experience a stroke each year, 5 to 14 percent will have an additional stroke within one year. A recent analysis examined the effects of ACTOS on the risk of stroke and other cardiovascular outcomes in patients with type 2 diabetes with and without prior stroke. The results showed that:

• • The incidence of recurrent stroke was reduced by 47 percent.
• • The combined risk of CV death, MI or stroke was reduced by 28 percent.
• • There was no effect of ACTOS on subsequent strokes in patients who had never experienced a stroke.

Improved Triglycerides & HDL-C

Additional data presented at the meeting showed that ACTOS improved components of diabetic dyslipidemia, a condition commonly found in people with type 2 diabetes and an important risk factor for CVD, the leading cause of death for people with type 2 diabetes. Diabetic dyslipidemia is characterized by increased triglycerides and decreased HDL-C. People with diabetic dyslipidemia also tend to have normal levels of LDL-C ("bad" cholesterol), but smaller, denser LDL-C particles that are likely to contribute to cholesterol build-up in arteries. The data indicated that:

• • ACTOS decreased triglycerides (a type of lipid or fat found in food and the body)
• • ACTOS increased HDL-C ("good" cholesterol)

"All of the results seen from the PROactive trial significantly impact the lives of those with type 2 diabetes and cardiovascular disease. Because they are at higher risk, it is important to find solutions that impact not only glycemic control but overall cardiovascular health. These findings show the potential benefits ACTOS can have in managing diabetes and the risk factors that contribute to cardiovascular disease," said Robert Spanheimer, M.D., senior medical director for Diabetes and Metabolism at Takeda Pharmaceuticals North America, Inc., in Lincolnshire, Illinois.

Notes to Editors

About the PROactive Study

PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Events)was a landmark study that prospectively looked at the impact in total mortality and macro-vascular morbidity using ACTOS, a glucose-lowering agent.^1,2 It was a randomized, double-blind, placebo-controlled outcome study of 5,238 patients with type 2 diabetes and macrovascular disease.^3,4,5 Patients were randomized to receive either ACTOS or placebo in addition to standard-of-care treatment⁶ (including the routine use of anti-hypertensives such as ACE inhibitors and beta blockers; glucose-lowering agents such as metformin, sulfonylureas and insulin; antiplatelet drugs such as aspirin, and lipid-modifying medicines such as statins and fibrates).⁷

This study focused on two key endpoints: a primary combination endpoint of seven different macrovascular events including both disease and procedural endpoints;8 and a principal secondary combination endpoint of death, heart attack and stroke.⁹

As reported at the European Association for the Study of Diabetes (EASD) Annual Meeting in September 2005, the primary endpoint was reduced by 10 percent but had not reached statistical significance by study end (P=0.095).¹⁰ The principal secondary endpoint showed that ACTOS significantly reduced the combined risk of heart attacks, strokes and death by 16 percent (P=0.027)¹¹ in high-risk patients with type 2 diabetes.¹²

About ACTOS

Takeda is the originator of thiazolidinedione derivatives and Actos® is a member of the thiazolidinedione class of "insulin-sensitizing" agents. Insulin sensitizers help improve the body's ability to effectively use its own insulin by reducing insulin resistance --- a defect that has been identified as a possible cause of type 2 diabetes.

In the United States, Takeda Pharmaceuticals North America, Inc. (TPNA), the U.S. marketing subsidiary wholly owned by Takeda, launched Actos® in August 1999. In Japan, Takeda launched Actos® in December 1999 and received the approval of marketing authorization in European Union in October 2000.
Actos® is now being marketed in approximately 70 countries by Takeda group companies and also by a worldwide partner for Actos®, Eli Lilly and Company, and other licensees.

1 Charbonnel E, Dormandy J, Erdmann E, Massi-Benedetti M. PROactive Study:
PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study In Type 2 Diabetic Patients Comparing Pioglitazone With Placebo In Addition To Existing Therapy. PowerPoint Presentation presented at 41st European Association for the Study of Diabetes Annual Meeting. 2005.

2 ACTOS Prescribing Information. Last updated August 2004.

3 Dormandy J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
The Lancet. 2005;366:1279-1289.

4 Dormandy J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
The Lancet. 2005;366:1279-1289.

5 Dormandy J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
The Lancet. 2005;366:1279-1289.

6 Dormandy J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
The Lancet. 2005;366:1279-1289.

7 Dormandy J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
The Lancet. 2005;366:1279-1289.

8 Dormandy J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
The Lancet. 2005;366:1279-1289.

9 Dormandy J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
The Lancet. 2005;366:1279-1289.

10 Charbonnel E, Dormandy J, Erdmann E, Massi-Benedetti M. PROactive Study:
PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study In Type 2 Diabetic Patients Comparing Pioglitazone With Placebo In Addition To Existing Therapy. PowerPoint Presentation presented at 41st European Association for the Study of Diabetes Annual Meeting. 2005.

11 Charbonnel E, Dormandy J, Erdmann E, Massi-Benedetti M. PROactive Study:
PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study In Type 2 Diabetic Patients Comparing Pioglitazone With Placebo In Addition To Existing Therapy. PowerPoint Presentation presented at 41st European Association for the Study of Diabetes Annual Meeting. 2005.

12 Charbonnel E, Dormandy J, Erdmann E, Massi-Benedetti M. PROactive Study:
PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study In Type 2 Diabetic Patients Comparing Pioglitazone With Placebo In Addition To Existing Therapy. PowerPoint Presentation presented at 41st European Association for the Study of Diabetes Annual Meeting. 2005.

# # #